Studies on the combination of HDM2 inhibitors with targeted compounds that also activate the p53 pathway through mechanisms other than HDM2 inhibition, may constitute a strategy to achieve more effective cancer treatments, but these are still scarce. The gene discussed is MDM2; the disease is cancer.